A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.

ABSTRACT: Breast cancer (BC) is a heterogeneous disease in which the tumor microenvironment (TME) seems to impact the clinical outcome. Here, we investigated whether a combination of gene expression signatures relating to both the structural and immune TME aspects can help predict prognosis in women with high-grade BC (HGBC). Thus, we focused on a combined molecular biomarker variable that involved extracellular matrix (ECM)-associated gene expression (ECM3 signature) and interferon (IFN)-associated metagene (IFN metagene) expression. In 97 chemo-naive HGBCs from the METABRIC dataset, the dichotomous ECM3/IFN (dECIF) variable identified a group of high-risk patients (ECM3⁺ /IFN^- vs other; hazard ratio = 3.2, 95% confidence interval: 1.5-6.7). Notably, ECM3⁺ /IFN

SUBMITTER: Lecchi M 

PROVIDER: S-EPMC8096783 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature